Japan Approves First RSV Vaccine Aimed at Adults 60 Years or Older
15:35 JST, September 26, 2023
The Health, Labor and Welfare Ministry on Monday formally approved the respiratory syncytial virus vaccine developed by British pharmaceutical company GSK PLC. It is the first time Japan has approved an RSV vaccine for use in adults aged 60 or older.
The RS virus causes symptoms like those of the common cold but can lead to severe pneumonia for those with weakened immune systems, including infants and elderly people.
According to GSK, the vaccine lowered the risk of pneumonia and bronchitis by about 80% in adults aged 60 or older in its vaccine efficacy trials.
U.S. pharmaceutical company Pfizer Inc. has also applied for approval of its RSV vaccine.
"Science & Nature" POPULAR ARTICLE
Japanese Government Unveils Liquefied CO2 Transportation Ship ‘Excool’
Bones from German Cave Rewrite Early History of Homo Sapiens
SLIM Lunar Probe Resumes Operation; Solar Panel Catching Light
SLIM Lander Powers Down for Long Lunar Night; JAXA Releases New Batch of Moon Snapshots
Advanced Helium-Cooled Reactor to be Given Power-Loss Test; Aim is to Verify Safety of Reactor Shutdown System
JN ACCESS RANKING
- Japan Eyes 45 B. Yen in Aid for Optical Semiconductors
- Business, Labor Leaders Reaffirm Vow to Raise Wages in Shunto Talks
- Japan Real Wages Fall at Steepest Pace in 9 Years in 2023
- Japan’s Job Availability Ratio Rises for 2nd Straight Year
- North Korean Workers in China Riot over Unpaid Wages; 2,000 Occupy Factory, Kill Plant Manager